November 4, 2025 — Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will participate in several upcoming healthcare conferences, including the American Heart Association (AHA) Scientific Sessions and The Liver Meeting 2025, to present data on its RNAi-based therapeutics.
Arrowhead will present a moderated poster on Zodasiran at the AHA Scientific Sessions on November 10. At The Liver Meeting 2025, Arrowhead will showcase data on Fazirsiran in patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.
Additionally, Arrowhead will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 19 and TD Cowen’s Virtual Treatment Advancements in Obesity & Related Disorders on November 24.
Presentation materials and webcast links, if available, can be found on the Events and Presentations page under the Investors section of Arrowhead’s website.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Source: Arrowhead Pharmaceuticals
